Cargando…

Dexamethasone induces docetaxel and cisplatin resistance partially through up-regulating Krüppel-like factor 5 in triple-negative breast cancer

PURPOSE: Dexamethasone (Dex), a glucocorticoid (GC), is used as a pretreatment drug in cancer patients undergoing chemotherapy. Dex functions by binding to the glucocorticoid receptor (GR) to prevent allergic reactions and severe chemotherapeutic side effects such as nausea and vomiting. However, th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Zhen, Dong, Jian, Zou, Tianning, Du, Chengzhi, Li, Siyuan, Chen, Ceshi, Liu, Rong, Wang, Kunhua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355285/ https://www.ncbi.nlm.nih.gov/pubmed/28030791 http://dx.doi.org/10.18632/oncotarget.14135

Ejemplares similares

Mithramycin A suppresses basal triple-negative breast cancer cell survival partially via down-regulating Krüppel-like factor 5 transcription by Sp1
por: Liu, Rong, et al.
Publicado: (2018)

Ataxin-3 like (ATXN3L), a member of the Josephin family of deubiquitinating enzymes, promotes breast cancer proliferation by deubiquitinating Krüppel-like factor 5 (KLF5)
por: Ge, Fei, et al.
Publicado: (2015)

Feasibility of metronomic chemotherapy with tegafur-uracil, cisplatin, and dexamethasone for docetaxel-refractory prostate cancer
por: Kubota, Hiroki, et al.
Publicado: (2017)

YD277 Suppresses Triple-Negative Breast Cancer Partially Through Activating the Endoplasmic Reticulum Stress Pathway
por: Chen, Zekun, et al.
Publicado: (2017)

Isochromanoindolenines suppress triple-negative breast cancer cell proliferation partially via inhibiting Akt activation
por: Jiang, Xiaoyan, et al.
Publicado: (2021)

Kruppel-like factor 8 regulates triple negative breast cancer stem cell-like activity
por: Le Minh, Giang, et al.
Publicado: (2023)

Mifepristone Derivative FZU-00,003 Suppresses Triple-negative Breast Cancer Cell Growth partially via miR-153-KLF5 axis
por: Liu, Rong, et al.
Publicado: (2020)

Docetaxel/cisplatin Therapy in Myasthenia Gravis with Hypertension/diabetes
por: Qi, Guoyan, et al.
Publicado: (2017)

Ilamycin E, a natural product of marine actinomycete, inhibits triple-negative breast cancer partially through ER stress-CHOP-Bcl-2
por: Zhou, Wenhui, et al.
Publicado: (2019)

ABT-737 ameliorates docetaxel resistance in triple negative breast cancer cell line
por: Hwang, Eunjoo, et al.
Publicado: (2018)

Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts
por: Martin, Miguel, et al.
Publicado: (2021)

The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
por: Johnson, Kai Conrad Cecil, et al.
Publicado: (2023)

Pyrrolo [3,4-b]-quinolin-9-amine compound FZU-0038-056 suppresses triple-negative breast cancer partially through inhibiting the expression of Bcl-2
por: Wang, Danping, et al.
Publicado: (2020)

Assessment of Concurrent Chemoradiotherapy plus Induction Chemotherapy in Advanced Nasopharyngeal Carcinoma: Cisplatin, Fluorouracil, and Docetaxel versus Gemcitabine and Cisplatin
por: Zeng, Zhen, et al.
Publicado: (2018)

HORMAD1 promotes docetaxel resistance in triple negative breast cancer by enhancing DNA damage tolerance
por: Zong, Beige, et al.
Publicado: (2021)

HORMAD1 promotes docetaxel resistance in triple negative breast cancer by enhancing DNA damage tolerance
por: Zong, Beige, et al.
Publicado: (2021)

Silencing of CXCR4 sensitizes triple-negative breast cancer cells to cisplatin
por: Liang, Sixian, et al.
Publicado: (2014)

Reversal of drug-resistance by noscapine chemo-sensitization in docetaxel resistant triple negative breast cancer
por: Doddapaneni, Ravi, et al.
Publicado: (2017)

CIB1 depletion with docetaxel or TRAIL enhances triple-negative breast cancer cell death
por: Chung, Alexander H., et al.
Publicado: (2019)

In Vitro and In Vivo Effects of Docetaxel and Dasatinib in Triple-Negative Breast Cancer: A Research Study
por: Passos, Ioannis D, et al.
Publicado: (2023)

Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin.
por: Hilkens, P. H., et al.
Publicado: (1997)

The methylenetetrahydrofolate reductase (MTHFR) C677T gene polymorphism is associated with breast cancer subtype susceptibility in southwestern China
por: Li, Zhen, et al.
Publicado: (2021)

Notch1 promotes resistance to cisplatin by up-regulating Ecto-5′-nucleotidase (CD73) in triple-negative breast cancer cells
por: Qi, Yuzhu, et al.
Publicado: (2023)

Characterization and phylogenetic analysis of Krüppel-like transcription factor (KLF) gene family in tree shrews (Tupaia belangeri chinensis)
por: Shao, Ming, et al.
Publicado: (2016)

Dexamethasone potentiates the antiangiogenic activity of docetaxel in castration-resistant prostate cancer
por: Wilson, C, et al.
Publicado: (2008)

Metformin suppresses triple-negative breast cancer stem cells by targeting KLF5 for degradation
por: Shi, Peiguo, et al.
Publicado: (2017)

Correction: Silencing of CXCR4 sensitizes triple-negative breast cancer cells to cisplatin
por: Liang, Sixian, et al.
Publicado: (2022)

KIF11 is required for proliferation and self-renewal of docetaxel resistant triple negative breast cancer cells
por: Jiang, Meng, et al.
Publicado: (2017)

Improved Anti-Triple Negative Breast Cancer Effects of Docetaxel by RGD-Modified Lipid-Core Micelles
por: Chen, Rujing, et al.
Publicado: (2021)

Potentiation of the Anticancer Effects by Combining Docetaxel with Ku-0063794 against Triple-Negative Breast Cancer Cells
por: Jeon, Ye-Won, et al.
Publicado: (2022)

Krüppel-Like Factor 4 Enhances Sensitivity of Cisplatin to Esophageal Squamous Cell Carcinoma (ESCC) Cells
por: Chen, Chuangui, et al.
Publicado: (2017)

Concurrent chemoradiotherapy with intravenous cisplatin and docetaxel for advanced oral cancer
por: Sato, Kotaro, et al.
Publicado: (2019)

Docetaxel versus docetaxel plus cisplatin for non-small-cell lung cancer: a meta-analysis of randomized clinical trials
por: Li, Ang, et al.
Publicado: (2017)

Targeting cuproptosis by zinc pyrithione in triple-negative breast cancer
por: Yang, Xu, et al.
Publicado: (2023)

Non-anthracycline-containing docetaxel and cyclophosphamide regimen is associated with sustained worse outcome compared with docetaxel, anthracycline and cyclophosphamide in neoadjuvant treatment of triple negative and HER2-positive breast cancer patients: updated follow-up data from NATT study
por: Chen, Xiaosong, et al.
Publicado: (2016)

Efficacy and Safety of Vinorelbine Plus Cisplatin vs. Gemcitabine Plus Cisplatin for Treatment of Metastatic Triple-Negative Breast Cancer After Failure with Anthracyclines and Taxanes
por: Wang, Junbin, et al.
Publicado: (2017)

Assessment of neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil in patients with oral cavity cancer
por: Fu, Jin Ye, et al.
Publicado: (2022)

Cisplatin as neoadjuvant chemotherapy in triple negative breast cancer: Exciting early results
por: Goel, Arun Kumar, et al.
Publicado: (2010)

Cisplatin-resistant triple-negative breast cancer subtypes: multiple mechanisms of resistance
por: Hill, David P., et al.
Publicado: (2019)

A Pilot Study of Extended Adjuvant Therapy with Metronomic Docetaxel for Patients with Operable Triple-Negative Breast Cancer
por: Abdelmaksoud, Bader A, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vi1c8do5fisk5sgufvnmcq7pi0